Functional sites of neuroleptic drug action in the human brain: PET/FDG studies with and without haloperidol

American Journal of Psychiatry

Volumn 153, Issue 1, 1996, Pages 41-49

  Holcomb, Henry H ^b   Cascella, Nicola G ^b   Thaker, Gunvant K ^b   Medoff, Deborah R ^b   Dannals, Robert F ^b   Tamminga, Carol A ^a  

^a MARYLAND PSYCHIATRIC RESEARCH CENTER   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

DOPAMINE 2 RECEPTOR; FLUORODEOXYGLUCOSE; HALOPERIDOL; NEUROLEPTIC AGENT; TRACER;

ADULT; ARTICLE; CLINICAL ARTICLE; DIAGNOSTIC ACCURACY; DISEASE CLASSIFICATION; DOPAMINE BLOOD LEVEL; DOSE RESPONSE; DRUG EFFECT; FEMALE; GLUCOSE BRAIN LEVEL; GLUCOSE METABOLISM; HUMAN; MALE; MENTAL DISEASE; NUCLEAR MAGNETIC RESONANCE IMAGING; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; SCHIZOPHRENIA; THALAMUS;

EID: 0030032509     PISSN: 0002953X     EISSN: None     Source Type: Journal    
DOI: 10.1176/ajp.153.1.41     Document Type: Article

References (62)

1. Delnay J, Deniker P: Le traitement des psychoses par une méthode neurolytique dérivée de l'hibernotherapie, in Congrès des Médecins Aliénistes et Neurologistes de France. Luxembourg, 1952, pp 497-502
2. Klein DF, Davis JM: Review of antipsychotic drug literature, in Diagnosis and Drug Treatment of Psychiatric Disorders. Baltimore, Williams & Wilkins, 1969, pp 52-138
3. Brandrup E, Kristjansen P: A controlled clinical test of a new psycholeptic drug (haloperidol). J Ment Sci 1961; 107:778-782
4. Carlsson A, Lindquist M: Effect of chlorpromazine or haloperidol on formation of 3-methoxytyramine and normetanephrine in mouse brain. Acta Pharmacol Toxicol 1963; 20:140-145
5. Creese I, Burt DR, Snyder SH: Dopamine receptor binding predicts clinical and pharmacological potencies of antischizophrenic drugs. Science 1976; 192:481-483
6. 2 subtypes of dopamine receptors in rat brain. J Neurosci 1986; 6:3177-3188
7. 2 dopamine receptors in drug-naive schizophrenics. Science 1986; 234:1558-1563
8. 2 dopamine receptor binding in the living human brain by PET. Science 1986; 231:258-261
9. 14C)-deoxyglucose method of measurement of local cerebral glucose utilization: theory, procedure and normal values in the conscious and anesthetized albino rat. J Neurochem 1977; 28:897-916
10. Kadekaro M, Vance WH, Terrell ML, Gary H Jr, Eisenberg HM, Sokoloff L: Effects of antidromic stimulation of the ventral root on glucose utilization in the ventral horn of the spinal cord in the rat. Proc Natl Acad Sci USA 1987; 84:5492-5495
11. Resnick SM, Gur RE, Alavi A, Gur RC, Reivich M: Positron emission tomography and subcortical glucose metabolism in schizophrenia. Psychiatry Res 1988; 24:1-11
12. Buchsbaum MS, Wu JC, DeLisi LE, Holcomb HH, Hazlett E, Copper-Langston K, Kessler R: Positron emission tomography studies of basal ganglia and somatosensory cortex neuroleptic drug effects: differences between normal controls and schizophrenic patients. Biol Psychiatry 1987; 22:479-494
13. Szechtman H, Nahmias C, Garnett ES, Firnau G, Brown GM, Kaplan RD, Cleghorn JM: Effect of neuroleptics on altered cerebral glucose metabolism in schizophrenia. Arch Gen Psychiatry 1988; 45:523-532
14. Cohen RM, Semple WE, Gross M, Nordahl TE, Holcomb HH, Dawling S, Pickar D: The effect of neuroleptics on dysfunction in a prefrontal substrate of sustained attention in schizophrenia. Life Sci 1988; 43:1141-1150
15. Wik G, Wiesel FA, Sjogren I, Blomqvist G, Greitz T, Stone-Elander S: Effects of sulpiride and chlorpromazine on regional cerebral glucose metabolism in schizophrenic patients as determined by positron emission tomography. Psychopharmacology (Berl) 1989; 97:309-318
16. Bartlett EJ, Wolkin A, Brodie JD, Laska EM, Wolf AP: Importance of pharmacologic control in PET studies: effects of thiothixene and haloperidol on cerebral glucose utilization in chronic schizophrenia. Psychiatry Res 1991; 40:115-124
17. Volkow ND, Brodie JD, Wolf AP, Angrist B, Russell J, Cancro R: Brain metabolism in patients with schizophrenia before and after acute neuroleptic administration. J Neurol Neurosurg Psychiatry 1986; 49:1199-1202
18. DeLisi LE, Holcomb HH, Cohen RM, Pickar D, Carpenter W, Morihisa JM, King AC, Kessler R, Buchsbaum MS: Positron emission tomography in schizophrenic patients with and without neuroleptic medication. J Cereb Blood Flow Metab 1985; 5: 201-206
19. Cleghorn JM, Szechtman H, Garnett ES, Nahmias C, Brown GM, Kaplan RD, Szechtman B, Franco S: Apomorphine effects on brain metabolism in neuroleptic-naive schizophrenic patients. Psychiatry Res: Neuroimaging 1991; 40:135-153
20. Rotrosen J: Effects of amphetamine on local cerebral metabolism in normal and schizophrenic subjects as determined by positron emission tomography. Psychopharmacology (Berl) 1987; 92: 241-246
21. Buchsbaum MS, Potkin SG, Siegel BV Jr, Lohr J, Katz M, Gottschalk LA, Gulasekaram B, Marshall JF, Lottenberg S, Teng CY: Striatal metabolic rate and clinical response to neuroleptics in schizophrenia. Arch Gen Psychiatry 1992; 49:966-974
22. 14C-deoxy-d-glucose incorporation into neostriatum and related structures in response to dopamine neuronal damage and apomorphine replacement. Brain Res 1980; 197:167-183
23. McCulloch J, Savaki HE, Sokoloff L: Distribution of effects of haloperidol on energy metabolism in the rat brain. Brain Res 1982; 234:81-90
24. Tarazi FI, Shirakawa O, Tamminga CA: Low-dose raclopride spares the extrapyramidal system in rat brain from metabolic effects. Eur J Pharmacol 1993; 232:71-77
25. Pizzolato G, Doncrant TT, Larson DM, Rapoport SI: Reduced metabolic response of rat brain to haloperidol greater after chronic treatment. Brain Res 1985; 337:1-9
26. Spitzer RL, Williams JBW: Structured Clinical Interview for DSM-III-R (SCID). New York, New York State Psychiatric Insitute, Biometrics Research, 1988
27. Dixon L, Thaker G, Conley R, Ross D, Cascella N, Tamminga C: Changes in psychopathology and dyskinesia after neuroleptic withdrawal in a double-blind design. Schizophr Res 1993; 10: 267-271
28. Overall JE, Gorham DR: The Brief Psychiatric Rating Scale. Psychol Rep 1962; 10:799-812
29. Harnacher K, Coenen HH, Stocklin G: Efficient stereospecific synthesis of no-carrier-added 2-[18F]-fluoro-2-deoxy-D-glucose using aminopolyether supported nucleophilic substitution. J Nucl Med 1986; 27:235-238
30. Phelps ME, Huang SC, Hoffman EJ, Selin C, Sokoloff L, Kuhl DE: Tomographic measurement of local cerebral glucose metabolic rate in humans with (F-18)2-fluoro-2-deoxy-D-glucose: validation of method. Ann Neurol 1979; 6:371-388
31. Talairach J, Tournoux P: Co-Planar Stereotaxic Atlas of the Human Brain. New York, Georg Thieme Verlag, 1988
32. Woods RP, Cherry SR, Mazziotta JC: Rapid automated algorithm for aligning and reslicing PET images. J Comput Assist Tomogr 1992; 16:620-633
33. Friston KJ, Frith CD, Liddle PF, Doaln RJ, Lammertsma AA, Frackowiak RSJ: The relationship between global and local changes in PET scans. J Cereb Blood Flow Metab 1990; 10:458-466
34. Friston KJ, Passingham RE, Nutt JG, Heather JD, Sawle GV, Frackowiak RSJ: Localization in PET images: direct fitting of the intercommissural (AC-PC) line. J Cereb Blood Flow Metab 1989; 9:690-695
35. Friston KJ, Frith CD, Liddle PF, Frackowiak RSJ: Plastic transformation of PET images. J Comp Assist Tomogr 1991; 15:634-639
36. Friston KJ, Frith CD, Liddle PF, Frackowiak RSJ: Comparing functional (PET) images: the assessment of significant change. J Cereb Blood Flow Metab 1991; 11:690-699
37. Brown MB, Engelman L, Jennrich RI: BMDP Statistical Software Manual, vol 2. Berkeley, University of California Press, 1990
38. Alexander GE, DeLong MR, Strick PL: Parallel organization of functionally segregated circuits linking basal ganglia and cortex. Ann Rev Neurosci 1986; 9:357-381
39. DeLong MR: Primate models of movement disorders of basal ganglia origin. Trends Neurosci 1990; 13:281-285
40. Weinberger DR, Berman KF, Zee RF: Physiologic dysfunction of dorso-lateral prefrontal cortex in schizophrenia, I: regional cerebral blood flow evidence. Arch Gen Psychiatry 1986; 43:114-124
41. Benes FM, Bird ED: An analysis of the arrangement of neurons in the cingulate cortex of schizophrenic patients. Arch Gen Psychiatry 1987; 44:608-616
42. Andreasen NC, Rezai K, Alliger R, Swayze VW II, Flaum M, Kirchner P, Cohen G, O'Leary DS: Hypofrontality in neuroleptic-naive patients and in patients with chronic schizophrenia: assessment with xenon 133 single-photon emission computed tomography and the Tower of London. Arch Gen Psychiatry 1992; 49:943-958
43. Kirkpatrick B, Buchanan RW, Maeda K, Carpenter WT Jr, Jauch D, Tamminga CA: Effect of neuroleptic withdrawal on plasma prolactin: a possible marker of receptor adaptation. Biol Psychiatry 1989; 26:131-138
44. Thaker GK, Wagman AM, Kirkpatrick B, Tamminga CA: Alterations in sleep polygraphy after neuroleptic withdrawal: a putative supersensitive dopaminergic mechanism. Biol Psychiatry 1989; 25:75-86
45. Graybiel AM: Neurotransmitters and neuromodulators in the basal ganglia. Trends Neurosci 1990; 13:244-254
46. Kapur S, Meyer J, Wilson AA, Houle S, Brown GM: Activation of specific cortical regions by apomorphine: an [0-15]H20 PET study in humans. Life Sci 1994; 176:21-24
47. Osborne PG, O'Connor WT, Beck O, Ungerstedt U: Acute versus chronic halopetidol: relationship between tolerance to catalepsy and striatal and accumbens dopamine, GABA and acetylcholine release. Brain Res 1994; 634:20-30
48. Tamminga CA, Thaker GK, Buchanan R, Kirkpatrick B, Alphs LD, Chase TN, Carpenter WT: Limbic system abnormalities identified in schizophrenia using positron emission tomography with fluorodeoxyglucose and neocortical alterations with deficit syndrome. Arch Gen Psychiatry 1992; 49:522-530
49. Suddath RL, Christison GW, Torrey EF, Casanova MF, Weinberger DR: Anatomical abnormalities in the brains of monozygotic twins discordant for schizophrenia. N Engl J Med 1990; 322:789-794
50. Bogerts B, Ashtari M, Degreef G, Alvir JM, Bilder RM, Lieberman JA: Reduced temporal limbic structure volumes on magnetic resonance images in first episode schizophrenia. Psychiatry Res 1990; 35:1-13
51. Scheibel AB, Kovelman JA: Disorientation of the hippocampal pyramidal cell and its processes in the schizophrenic patient (letter). Biol Psychiatry 1981; 16:101-102
52. Falkai P, Bogerts B: Cell loss in the hippocampus of schizophrenics. Eur Arch Psychiatry Neurol Sci 1986; 236:154-161
53. Jeste DV, Lohr JB: Hippocampal pathologic findings in schizophrenia. Arch Gen Psychiatry 1989; 46:1019-1026
54. Bogerts B, Meertz E, Schonfeldt-Bausch R: Basal ganglia and limbic system pathology in schizophrenia: a morphometric study of brain volume and shrinkage. Arch Gen Psychiatry 1985; 42: 784-791
55. Jakob H, Beckmann H: Prenatal developmental disturbances in the limbic allocortex in schizophrenics. J Neural Transm 1986; 65:303-326
56. Benes FM, Vincent SL, Alsterberg G, Bird ED, SanGiovanni JP: Increased GABAA receptor binding in superficial layers of cingulate cortex in schizophrenics. J Neurosci 1992; 12:924-929
57. Weinberger DR, Wagner RL, Wyatt RJ: Neuropathological studies of schizophrenia: a selective review. Schizophr Bull 1983; 9: 193-212
58. Heimer L, Wilson RD: The subcortical projections of the allocortex: similarities in the neural associations of the hippocampus, the piriform cortex, and the neocortex, in Santini Golgi Centennial Symposium. New York, Raven Press, 1975, pp 177-193
59. Teuber HL: Complex functions of the basal ganglia, in Basal Ganglia. Edited by Yahr M. New York, Raven Press, 1976, pp 151-168
60. Nauta WJH: Reciprocal links of the corpus striatum with the cerebral cortex and limbic system: a common substrate for movement and thought? in Neurology and Psychiatry: A Meeting of Minds. Edited by Mueller J. Basel, Karger, 1989, pp 43-63
61. Biegon A, Kargman S, Snyder L, McEwen BS: Characterization and localization of serotonin receptors in human brain postmortem. Brain Res 1986; 363:91-98
62. 2-Family receptors in schizophrenia: distribution and implications for treatment. Clin Neuropharmacology 1995; 18(suppl 1):S110-S120